Avzivi (bevacizumab-tnjn) / Bio-Thera Solutions, Cipla, BeOne Medicines, Biomm, Mega Lifesciences, Sandoz - LARVOL DELTA

Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer (clinicaltrials.gov) - P3 | N=255 | Not yet recruiting | Sponsor: National Cancer Institute (NCI)

New P3 trial • pMMR • Endometrial Cancer • Oncology • Solid Tumor

Exposure-safety Markov modeling of ocular adverse events in patient populations treated with tisotumab vedotin. (PubMed, J Pharmacokinet Pharmacodyn) - P1/2, P2 | "A total of 757 patients who received TV as monotherapy or combination (with carboplatin, bevacizumab, or pembrolizumab) across seven clinical studies were included in this analysis. Based on the totality of data from clinical outcomes, pharmacokinetics, and E-R analyses, as well as DTMM modeling results, TV 1.7 mg/kg every 2 weeks may provide higher efficacy with slightly increased risk of OAEs compared with 2.0 mg/kg Q3W, although these OAEs are manageable with an appropriate eye care plan. ClinicalTrials.gov ID (first submission): NCT03485209 (2018-03-08), NCT03657043 (2018-08-22), NCT03438396 (2018-02-08), NCT03786081 (2018-12-13), NCT03913741 (2019-03-29), NCT02001623 (2013-11-14), and NCT02552121 (2015-09-14)."

Adverse events • Journal • Cervical Cancer • Oncology • Solid Tumor

Clinical Trial of an Anti-cancer Drug, CA-4948 (Emavusertib), in Combination With Chemotherapy Treatment (FOLFOX Plus Bevacizumab) in Metastatic Colorectal Cancer (clinicaltrials.gov) - P1 | N=24 | Recruiting | Sponsor: National Cancer Institute (NCI) | Initiation date: Jan 2026 ➔ Jun 2025

Trial initiation date • Colorectal Adenocarcinoma • Colorectal Cancer • Oncology • Solid Tumor

A092001: Chemotherapy With or Without Immunotherapy for Peritoneal Mesothelioma (clinicaltrials.gov) - P2 | N=66 | Recruiting | Sponsor: National Cancer Institute (NCI) | Trial completion date: Aug 2025 ➔ Aug 2026 | Trial primary completion date: Aug 2025 ➔ Aug 2026

Trial completion date • Trial primary completion date • Mesothelioma • Oncology • Peritoneal Mesothelioma • Psoriatic Arthritis • Solid Tumor

NCI-2018-01503: Bevacizumab and Anetumab Ravtansine or Paclitaxel in Treating Patients With Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (clinicaltrials.gov) - P2 | N=96 | Active, not recruiting | Sponsor: National Cancer Institute (NCI) | Trial completion date: Oct 2025 ➔ Oct 2026 | Trial primary completion date: Oct 2025 ➔ Oct 2026

Platinum resistant • Trial completion date • Trial primary completion date • Fallopian Tube Cancer • High Grade Serous Ovarian Cancer • Oncology • Ovarian Cancer • Peritoneal Cancer • Refractory Ovarian Cancer • Solid Tumor • MSLN

ZIABC011078: Testing Atezolizumab Alone or Atezolizumab Plus Bevacizumab in People With Advanced Alveolar Soft Part Sarcoma (clinicaltrials.gov) - P2 | N=63 | Active, not recruiting | Sponsor: National Cancer Institute (NCI) | Trial completion date: Oct 2025 ➔ Oct 2026 | Trial primary completion date: Oct 2025 ➔ Oct 2026

IO biomarker • Trial completion date • Trial primary completion date • Alveolar Soft Tissue Sarcoma • Oncology • Sarcoma • Solid Tumor

CALGB 40603: Paclitaxel With or Without Carboplatin and/or Bevacizumab Followed by Doxorubicin and Cyclophosphamide in Treating Patients With Breast Cancer That Can Be Removed by Surgery (clinicaltrials.gov) - P2 | N=454 | Completed | Sponsor: National Cancer Institute (NCI) | Active, not recruiting ➔ Completed | Trial completion date: Feb 2026 ➔ Sep 2025

Trial completion • Trial completion date • Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • Inflammatory Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer • ER • HER-2 • PGR

Modified Immune Cells (Autologous Dendritic Cells) and a Vaccine (Prevnar) Combined With Immune Checkpoint Inhibition After High-Dose External Beam Radiation Therapy in Treating Patients With Unresectable Liver Cancer (clinicaltrials.gov) - P1/2 | N=85 | Recruiting | Sponsor: Mayo Clinic | N=54 ➔ 85

Checkpoint inhibition • Enrollment change • Biliary Cancer • Cholangiocarcinoma • Hepatocellular Cancer • Liver Cancer • Oncology • Solid Tumor

External Beam Radiation Therapy and Brachytherapy With Chemotherapy and Immunotherapy for the Treatment of Stage IVB Cervical Cancer (clinicaltrials.gov) - P1/2 | N=35 | Recruiting | Sponsor: Jonsson Comprehensive Cancer Center | Not yet recruiting ➔ Recruiting

Enrollment open • Cervical Adenocarcinoma • Cervical Cancer • Cervical Squamous Cell Carcinoma • Oncology • Solid Tumor • Squamous Cell Carcinoma

Testing the Addition of Atezolizumab to Combination Chemotherapy or Atezolizumab Alone for Metastatic Colon or Rectal Cancer, the COMMIT Study (clinicaltrials.gov) - P3 | N=120 | Active, not recruiting | Sponsor: National Cancer Institute (NCI) | Suspended ➔ Active, not recruiting

dMMR • Enrollment closed • Mismatch repair • MSI-H • Colon Adenocarcinoma • Colon Cancer • Colorectal Adenocarcinoma • Colorectal Cancer • Microsatellite Instability • Oncology • Rectal Cancer • Solid Tumor • MLH1 • MSH2 • MSH6 • MSI

A Study to Determine Whether Chemotherapy and Atezolizumab is Better Than Chemotherapy, Bevacizumab and Atezolizumab in Patients With Advanced Liver Cancer (clinicaltrials.gov) - P2 | N=88 | Active, not recruiting | Sponsor: National Cancer Institute (NCI) | Trial completion date: Dec 2025 ➔ Mar 2026 | Trial primary completion date: Dec 2025 ➔ Mar 2026

Trial completion date • Trial primary completion date • Biliary Cancer • Cholangiocarcinoma • Hepatocellular Cancer • Liver Cancer • Oncology • Psoriatic Arthritis • Solid Tumor • IL2

Testing Immunotherapy With or Without Stereotactic Body Radiation Therapy in Patients With Advanced Liver Cancer, HELIO-RT Trial (clinicaltrials.gov) - P3 | N=252 | Not yet recruiting | Sponsor: NRG Oncology

New P3 trial • Hepatocellular Cancer • Liver Cancer • Oncology • Solid Tumor

Matching-adjusted indirect comparison of tislelizumab plus lenvatinib versus sintilimab plus bevacizumab biosimilar as first-line treatment for unresectable hepatocellular carcinoma. (PubMed, Front Immunol) - P2, P2/3 | "Sensitivity analysis by two different methods supported the findings from the primary MAIC analysis. This MAIC analysis demonstrated that tislelizumab plus lenvatinib achieved superior efficacy, with higher ORR and longer PFS and OS compared to sintilimab plus bevacizumab biosimilar in untreated Chinese patients with uHCC."

Clinical • Journal • Hepatocellular Cancer • Oncology • Solid Tumor • PD-L1

Cediranib Maleate and Olaparib Compared to Bevacizumab in Treating Patients With Recurrent Glioblastoma (clinicaltrials.gov) - P2 | N=70 | Active, not recruiting | Sponsor: National Cancer Institute (NCI) | Trial completion date: Jul 2025 ➔ Jul 2026

Trial completion date • Brain Cancer • Glioblastoma • Oncology • Solid Tumor

Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer (clinicaltrials.gov) - P3 | N=692 | Active, not recruiting | Sponsor: National Cancer Institute (NCI) | Trial completion date: Jun 2025 ➔ Jul 2026

Trial completion date • Fallopian Tube Cancer • Oncology • Ovarian Cancer • Ovarian Serous Adenocarcinoma • Peritoneal Cancer • Solid Tumor

A phase 2 study of tislelizumab combined with bevacizumab and chemotherapy as first-line treatment for persistent, recurrent, or metastatic cervical cancer. (PubMed, EClinicalMedicine) - P2 | "Patients received tislelizumab (200 mg), bevacizumab (7.5 mg/kg), paclitaxel (175 mg/m2), and cisplatin (50 mg/m2) or carboplatin (AUC = 5) on day 1 of cycle 1 (every 3 weeks) in safety run-in stage. This work was supported by grants from the Pioneer R&D Program of Zhejiang (2023SDYXS0001, 2022C03031) and by BeiGene (Beijing) Co., Ltd. The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript."

Journal • P2 data • Cervical Cancer • Hematological Disorders • Oncology • Renal Disease • Solid Tumor

Osimertinib With or Without Bevacizumab in Treating Patients With EGFR Positive Non-small Cell Lung Cancer and Brain Metastases (clinicaltrials.gov) - P2 | N=7 | Active, not recruiting | Sponsor: National Cancer Institute (NCI) | N=112 ➔ 7 | Trial completion date: Jul 2025 ➔ Jul 2026 | Trial primary completion date: Jul 2025 ➔ Feb 2025

Enrollment change • Trial completion date • Trial primary completion date • Brain Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

Primary efficacy and safety results of BAT1308, a PD-1 inhibitor, + chemotherapy ± bevacizumab in phase 2 trial for persistent, recurrent, or metastatic cervical cancer. (ASCO 2025) - P2/3 | "Patients received BAT1308 (300 mg Q3W for up to 24 months) plus platinum-based chemotherapy (paclitaxel 175 mg/m2 + cisplatin 50 mg/ m2 or carboplatin AUC 5) and, per investigator discretion, bevacizumab (15 mg/kg). BAT1308 combined with platinum-based chemotherapy ± Bevacizumab as first-line therapy showed durable anti-tumor activity and manageable safety profile for PD-L1-positive (CPS ≥ 1) persistent, recurrent or metastatic cervical cancer. These data are consistent with the earlier results and provide support for further studies."

Clinical • Metastases • P2 data • Alopecia • Anemia • Cervical Cancer • Immunology • Neutropenia • Oncology • Solid Tumor • Squamous Cell Carcinoma • Thrombocytopenia

Testing the Addition of ASTX660 (Tolinapant) to the Usual Chemotherapy Treatment (Paclitaxel With or Without Bevacizumab) in Patients With Recurrent Ovarian Cancer (clinicaltrials.gov) - P1/2 | N=0 | Withdrawn | Sponsor: National Cancer Institute (NCI) | N=127 ➔ 0 | Not yet recruiting ➔ Withdrawn

Enrollment change • Trial withdrawal • Carcinosarcoma • Epithelial Ovarian Cancer • Fallopian Tube Cancer • High Grade Serous Ovarian Cancer • Oncology • Ovarian Cancer • Peritoneal Cancer • Refractory Ovarian Cancer • Sarcoma • Solid Tumor

Paclitaxel, Carboplatin, and Bevacizumab or Paclitaxel, Carboplatin, and Temsirolimus or Ixabepilone, Carboplatin, and Bevacizumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer (clinicaltrials.gov) - P2 | N=349 | Active, not recruiting | Sponsor: National Cancer Institute (NCI) | Trial completion date: Mar 2025 ➔ Mar 2026

Trial completion date • Carcinosarcoma • Endometrial Adenocarcinoma • Endometrial Cancer • Endometrial Serous Adenocarcinoma • Oncology • Sarcoma • Solid Tumor • Uterine Cancer • AKT1

Liberty-201: A Study Investigating the Efficacy and Safety of LBL-007 Plus Tislelizumab in Combination With Bevacizumab Plus Fluoropyrimidine Versus Bevacizumab Plus Fluoropyrimidine in Participants With Unresectable or Metastatic Colorectal Cancer (clinicaltrials.gov) - P1/2 | N=113 | Active, not recruiting | Sponsor: BeiGene | Trial completion date: Apr 2026 ➔ Dec 2026 | Trial primary completion date: Apr 2026 ➔ May 2025

Mismatch repair • pMMR • Trial completion date • Trial primary completion date • Colorectal Cancer • Oncology • Solid Tumor • PD-L1

NRG-GY036: Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer (clinicaltrials.gov) - P3 | N=880 | Recruiting | Sponsor: NRG Oncology | Not yet recruiting ➔ Recruiting | Trial completion date: Dec 2035 ➔ Dec 2034

Enrollment open • Trial completion date • Fallopian Tube Cancer • High Grade Serous Ovarian Cancer • Oncology • Ovarian Cancer • Solid Tumor • BRCA

External Beam Radiation Therapy and Brachytherapy With Chemotherapy and Immunotherapy for the Treatment of Stage IVB Cervical Cancer (clinicaltrials.gov) - P1/2 | N=35 | Not yet recruiting | Sponsor: Jonsson Comprehensive Cancer Center | Trial completion date: Jan 2031 ➔ Jan 2032 | Initiation date: Jan 2025 ➔ Jan 2026 | Trial primary completion date: Jan 2030 ➔ Jan 2031

Trial completion date • Trial initiation date • Trial primary completion date • Cervical Adenocarcinoma • Cervical Cancer • Cervical Squamous Cell Carcinoma • Oncology • Solid Tumor • Squamous Cell Carcinoma

ECOG-ACRIN EA3202: Testing the Use of Investigational Drugs Atezolizumab and/or Bevacizumab With or Without Standard Chemotherapy in the Second-Line Treatment of Advanced-Stage Head and Neck Cancers (clinicaltrials.gov) - P2/3 | N=430 | Active, not recruiting | Sponsor: National Cancer Institute (NCI) | Recruiting ➔ Active, not recruiting

Checkpoint inhibition • Enrollment closed • IO biomarker • Head and Neck Cancer • Hypopharyngeal Cancer • Laryngeal Cancer • Lung Cancer • Nasopharyngeal Carcinoma • Oncology • Oral Cancer • Oropharyngeal Cancer • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck • Squamous Cell Skin Cancer • PD-L1

Clinical Trial of an Anti-cancer Drug, CA-4948 (Emavusertib), in Combination With Chemotherapy Treatment (FOLFOX Plus Bevacizumab) in Metastatic Colorectal Cancer (clinicaltrials.gov) - P1 | N=24 | Recruiting | Sponsor: National Cancer Institute (NCI) | Not yet recruiting ➔ Recruiting | Trial completion date: Oct 2025 ➔ Dec 2026 | Initiation date: Apr 2025 ➔ Jan 2026 | Trial primary completion date: Oct 2025 ➔ Dec 2026

Enrollment open • Trial completion date • Trial initiation date • Trial primary completion date • Colorectal Adenocarcinoma • Colorectal Cancer • Oncology • Solid Tumor